Methods: Vaccination coverage data was collected during the vaccination clinics in February and April. In collaboration with college X, the Rhode Island Department of Health (RI DOH), and the Centers for Disease Prevention and Control (CDC), strategies were reviewed and culture results were obtained. Informal question and answer sessions with university and DOH staff were conducted.
Results: In February 2015, two culture-confirmed cases of N. meningitidis serogroup B (MenB) meningitis were observed, resulting in an attack rate of 44 per 100,000. This attack rate signified a 489-fold increase in MenB disease in 17-22 year olds in the United States, and thus represented an outbreak within the college’s community. Within 3 days of the identification of the second case, a rapid collaboration among the RI DOH, CDC, and college X allowed for the vaccination of 3061 students (and catch-up clinics later the same week vaccinated 464 students), preventing any further cases of N. meningitidis serogroup B infections to date. A coverage rate of 94% (n= 3525) was achieved.
Conclusion: This outbreak marks the first time that Trumenba™ has been used as an intervention response to an outbreak, and allowed us a unique opportunity to monitor adverse events following vaccination with TrumenbaTM.
N. Alexander-Scott, None
P. H. Dennehy, None